Trevi Therapeutics Investor Relations Material

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for serious neurological conditions. The company's lead therapeutic candidate targets chronic pruritus (itching) and other disorders related to the central and peripheral nervous systems. Trevi's drug development efforts aim to address unmet needs in conditions where current therapies are limited or ineffective. The company serves the healthcare sector, particularly in neurology and dermatology, with a focus on advancing innovative solutions for challenging medical conditions. The company is headquartered in New Haven, Connecticut, and its shares are listed on the NASDAQ.